Characterization of thromboxane A2/prostaglandin H2 receptors in human vascular smooth muscle cells. 1990

T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston 29425.

The present study utilizes a newly synthesized TXA2/PGH2 mimetic, I-BOP, to characterize the TXA2/PGH2 receptor in suspensions of cultured human vascular smooth muscle cells. [125I]-BOP bound in a saturable and specific manner (Kd = 2.6 +/- 0.6 nM; Bmax = 33,540 +/- 6,200 sites/cell; 69 fmoles/mg protein, n = 12). Competition binding assays were performed with [125I]-BOP and the TXA2/PGH2 receptor antagonists SQ29548, L657925 and L657926 and the receptor agonist U46619. I-BOP induced concentration-dependent increases in intracellular free calcium which were inhibited by SQ29548. The results provide radioligand binding evidence for the presence of a TXA2/PGH2 receptor in human vascular smooth muscle cells.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D011449 Prostaglandin Endoperoxides Precursors in the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. They are physiologically active compounds, having effect on vascular and airway smooth muscles, platelet aggregation, etc. Endoperoxides, Prostaglandin
D011463 Prostaglandins H A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin H2.
D011982 Receptors, Prostaglandin Cell surface receptors that bind prostaglandins with high affinity and trigger intracellular changes which influence the behavior of cells. Prostaglandin receptor subtypes have been tentatively named according to their relative affinities for the endogenous prostaglandins. They include those which prefer prostaglandin D2 (DP receptors), prostaglandin E2 (EP1, EP2, and EP3 receptors), prostaglandin F2-alpha (FP receptors), and prostacyclin (IP receptors). Prostaglandin Receptors,Prostaglandin Receptor,Receptor, Prostaglandin,Receptors, Prostaglandins,Prostaglandins Receptors
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
January 1987, Federation proceedings,
T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
October 1992, Biochimica et biophysica acta,
T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
December 1993, The Journal of pharmacology and experimental therapeutics,
T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
September 1989, Biochemical pharmacology,
T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
September 1989, The Journal of pharmacology and experimental therapeutics,
T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
July 1991, The Journal of pharmacology and experimental therapeutics,
T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
December 1985, Circulation,
T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
August 1989, Biochemical and biophysical research communications,
T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
July 1992, The Journal of pharmacology and experimental therapeutics,
T A Morinelli, and D E Mais, and J E Oatis, and A J Crumbley, and P V Halushka
February 1989, The American journal of physiology,
Copied contents to your clipboard!